Global

‡ In these countries please contact our distributor

WOCNext 2019

WOCNext 2019

June 23-25, Nashville, TN
Booth #713

WOCNext is the premier event for nursing professionals to convene and learn about the latest evidence-based practices and innovations in wound, ostomy and continence care. It will equip you with the experience you need to advance your knowledge, patient care and professional practice to the next level.

Smith & Nephew is a world-wide leader, providing clinical and economic solutions that prevent and treat chronic, acute and traumatic wounds. Throughout its 150+ year heritage, Smith & Nephew has been dedicated to improving the lives of people suffering from serious wounds by providing innovative products like PICO, RENASYS, ALLEVYN and ACTICOAT.

Visit us at booth #713 or attend a breakfast symposia to understand the Smith & Nephew solution for pressure injury prevention, infection management and negative pressure wound therapy.

 

MSTE36-16685-0619

 

(C) 2019 Smith & Nephew, Inc.

Symposia schedule

Monday, June 24, 2019
7:00 AM – 8:30 AM
Breakfast

Pressure Injuries on the Fast Track: A closer look at Medical-Device Related Pressure Injuries, Emergent and Urgent Care Challenges SOLD OUT

Speakers
Melody Austin, MSN, RN, CWOCN, CNS, CWON-AP
Lee Ruotsi, MD

More info >

 

Tuesday, June 25, 2019:
7:00 AM – 8:30 AM
Breakfast

New Clinical Evidence that Changes the Game With NPWT (S10)  SOLD OUT

Speakers
Elizabeth Huddleston, PhD
Kristi Huebner, MSN, RN, CWS
Leo Nherera

More info >

New evidence

Healthcare Resource Utilization of Stage 3 & Stage 4 Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) Patients Treated Early with Clostridial Collagenase Ointment (CCO)
Early use of Collagenase SANTYL Ointment 250 units/g (0-30 days from Dx) lowers wound care specific costs by $9,240 over 1 year for Stage 3 and 4 PUs and $2,755 for DFUs compared to Santyl started later (days 31-90).  Additionally, early use of SANTYL results in less SANTYL use and therefore less spend on SANTYL.  The early use of SANTYLcan help a facility or payer reduce its SANTYL spend if it’s used earlier in the wound episode and if it’s not delayed as a step edit or through dose limits.
Poster #R08

The Incremental Cost of Surgical Site Complications & Infections Across Multiple Surgical Indications
Mean incremental cost of SSI across all indications was $14,945.21; an increase of 84%. SSI added on average 6.1 days to patients length of stay. Non SSI complications also had significant implications, incurring incremental cost of $7,558.76 and increasing length of stay by 2.8 days. 34.4% of patients suffering post-surgical complications had a subsequent hospital stay within 90 days of discharge.
Poster #R06

 

Collagenase SANTYL Ointment 250 units/gram is indicated for debriding chronic dermal ulcers and severely burned areas. Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone. Use of Collagenase SANTYL Ointment should be terminated when debridement is complete and granulation tissue is well established. See complete prescribing information for more details.